Planned Solutions Inc. Sells 1,150 Shares of Sanofi (NASDAQ:SNY)

Planned Solutions Inc. lessened its stake in shares of Sanofi (NASDAQ:SNY) by 18.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,068 shares of the company’s stock after selling 1,150 shares during the quarter. Planned Solutions Inc.’s holdings in Sanofi were worth $244,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in SNY. Northwest Investment Counselors LLC acquired a new position in Sanofi during the 3rd quarter worth approximately $29,000. Concord Wealth Partners increased its holdings in shares of Sanofi by 157.8% during the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after acquiring an additional 363 shares in the last quarter. Fortitude Family Office LLC increased its holdings in shares of Sanofi by 708.6% during the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock valued at $43,000 after acquiring an additional 659 shares in the last quarter. Sunbelt Securities Inc. raised its position in shares of Sanofi by 72.1% during the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after purchasing an additional 313 shares during the period. Finally, Versant Capital Management Inc bought a new position in shares of Sanofi in the 4th quarter worth $54,000. Institutional investors own 14.04% of the company’s stock.

Sanofi Stock Performance

Shares of Sanofi stock opened at $51.69 on Wednesday. Sanofi has a 52 week low of $45.22 and a 52 week high of $58.97. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The business has a 50 day moving average price of $48.46 and a 200-day moving average price of $52.15. The company has a market cap of $131.18 billion, a PE ratio of 26.37, a price-to-earnings-growth ratio of 1.25 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $1.35. The business had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. Sanofi’s revenue was up 12.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.55 earnings per share. Equities analysts anticipate that Sanofi will post 3.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Two analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.